.Pharmacolibrary.Drugs.ATC.B.B06AC05 .Pharmacolibrary.Drugs.ATC.B.B06AC05| name: | Lanadelumab |
| ATC code: | B06AC05 | route: | subcutaneous |
| n-compartments | 2 |
Lanadelumab is a fully human monoclonal antibody that inhibits plasma kallikrein and is used as a prophylactic treatment to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years or older. It is approved by regulatory agencies including the FDA and EMA.
Pharmacokinetic parameters observed in healthy volunteers and patients with hereditary angioedema (HAE), based on population pharmacokinetic analysis. Subjects included males and females, mainly adults, with subcutaneous administration.
Wang, Y, et al., & Martin, P (2020). Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema. Clinical and translational science 13(6) 1208–1216. DOI:10.1111/cts.12806 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32407574